A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

NCT02563106 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile
Clostridium Infections

Interventions

DRUG: SYN-004
DRUG: Placebo

Sponsor

Theriva Biologics, Inc.